| Kumli Anye, | |
|
12311 Snowden Woods Rd, Laurel, MD 20708-2492 | |
| (240) 603-1253 | |
| Not Available |
| Full Name | Kumli Anye |
|---|---|
| Gender | Female |
| Speciality | Nurse Practitioner |
| Experience | 10 Years |
| Location | 12311 Snowden Woods Rd, Laurel, Maryland |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1104221613 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Revival Homecare Agency | Upper marlboro, MD | Home health agency |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mandm Behavioral Health Solutions | 1355634437 | 6 |
| Della Behavioral Health Services | 3971755000 | 52 |
News Archive
If you already have the sequenced map of an organism's genome but want to look for structural oddities in a sample, you can check the genomic barcode - a series of distances between known, targeted sites - by cutting a DNA sequence at those sites and examining the distance between the cuts.
Lawmakers in Maryland, Nebraska and Kansas consider bills to advance or block the marketplaces; California officials wrestle with the nitty gritty of implementation.
The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
› Verified 1 days ago
| Entity Name | Andres Salazar P A |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1811041528 PECOS PAC ID: 3870587322 Enrollment ID: O20070830000110 |
News Archive
If you already have the sequenced map of an organism's genome but want to look for structural oddities in a sample, you can check the genomic barcode - a series of distances between known, targeted sites - by cutting a DNA sequence at those sites and examining the distance between the cuts.
Lawmakers in Maryland, Nebraska and Kansas consider bills to advance or block the marketplaces; California officials wrestle with the nitty gritty of implementation.
The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
› Verified 1 days ago
| Entity Name | Della Behavioral Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1750635207 PECOS PAC ID: 3971755000 Enrollment ID: O20121218000204 |
News Archive
If you already have the sequenced map of an organism's genome but want to look for structural oddities in a sample, you can check the genomic barcode - a series of distances between known, targeted sites - by cutting a DNA sequence at those sites and examining the distance between the cuts.
Lawmakers in Maryland, Nebraska and Kansas consider bills to advance or block the marketplaces; California officials wrestle with the nitty gritty of implementation.
The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
› Verified 1 days ago
| Entity Name | M&m Behavioral Health Solutions |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1134525710 PECOS PAC ID: 1355634437 Enrollment ID: O20160727000859 |
News Archive
If you already have the sequenced map of an organism's genome but want to look for structural oddities in a sample, you can check the genomic barcode - a series of distances between known, targeted sites - by cutting a DNA sequence at those sites and examining the distance between the cuts.
Lawmakers in Maryland, Nebraska and Kansas consider bills to advance or block the marketplaces; California officials wrestle with the nitty gritty of implementation.
The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kumli Anye, 12311 Snowden Woods Rd, Laurel, MD 20708-2492 Ph: () - | Kumli Anye, 12311 Snowden Woods Rd, Laurel, MD 20708-2492 Ph: (240) 603-1253 |
News Archive
If you already have the sequenced map of an organism's genome but want to look for structural oddities in a sample, you can check the genomic barcode - a series of distances between known, targeted sites - by cutting a DNA sequence at those sites and examining the distance between the cuts.
Lawmakers in Maryland, Nebraska and Kansas consider bills to advance or block the marketplaces; California officials wrestle with the nitty gritty of implementation.
The U.S. Food and Drug Administration today recommended more conservative dosing guidelines for Erythropoiesis-Stimulating Agents (ESAs) when used to treat anemia in patients with chronic kidney disease (CKD) because of the increased risks of cardiovascular events such as stroke, thrombosis, and death.
Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today that it has initiated a Phase 2, randomized, double-blind, placebo-controlled study evaluating SGX942, a first-in-class innate defense regulator, as a treatment for oral mucositis in patients undergoing chemoradiation therapy for head and neck cancer.
› Verified 1 days ago
Judith Tangi, CRNP-PMH Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 8125 Mallard Shore Dr, Laurel, MD 20724 Phone: 240-838-4012 | |
Ms. Gloria Asiamah Fosu, RN, MSN, PMHMP-BC Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 14502 Greenview Dr Suit 455, Laurel, MD 20708 Phone: 240-752-4513 | |
Mrs. Bodil Lynn Morris, CRNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 13801 Belle Chasse Blvd, Unit 211, Laurel, MD 20707 Phone: 407-232-5062 | |
Ms. Florence A Nwana, CRNP-PMH Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 13639 Baltimore Ave, Laurel, MD 20707 Phone: 301-604-4830 Fax: 301-604-4929 | |
Making Mpaka, Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 16305 Gales Ct, Laurel, MD 20707 Phone: 301-404-0726 | |
Akukeng Mba, Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 13208 Deerfield Rd, Laurel, MD 20708 Phone: 301-793-4761 | |
Bolanle Akinrebiyo, Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 10133 Summer Glow Walk, Laurel, MD 20723 Phone: 202-631-7228 |